[Ip-health] Mail & Guardian: Anger over drug access in TB trial

Thiru Balasubramaniam thiru at keionline.org
Fri Jul 5 02:43:33 PDT 2013


http://mg.co.za/article/2013-07-05-00-anger-over-drug-access-in-tb-trial

Anger over drug access in TB trial

05 JUL 2013 00:00 MARA KARDAS-NELSON

A new combination treatment has been tested in Southern Africa, but it
is not available locally.

Health activists in the United States and South Africa are crying foul
about a drug that was tested in South Africa, Zambia, Botswana
and Zimbabwe, despite it not being registered in any of those countries and
therefore not available to patients other than those involved in
the clinical trial.

They also say that the drug, rifapentine, is far too expensive. Although
there is no South African price for the drug, it is currently $1.60
a tablet in the United States, compared with five US cents a tablet for
isoniazid, a drug currently used in tuberculosis regimens.

Although rifapentine has been used to treat selected American TB patients
for years, it is largely unavailable outside of the US. This is partly
owing to its high cost and partly as a result of little research having
been done on the drug. Previous trials involving rifapentine have been
disappointing, sporting high TB relapse rates and high rates of resistance
in patients living with HIV.

But the results of a new study that were released earlier this year that
stemmed from trials in different parts of Southern Africa showed that using
rifapentine in conjunction with another up–and–coming TB drug,
moxifloxacin, was just as effective as using isoniazid or rifampicin, the
currently used drugs. The results were positive even in patients with HIV.

Notably, patients involved in the rifapentine arm of the trial only had to
take the drugs once weekly, as opposed to twice daily as in
current regimens.

"If you think about a bus driver [on TB medicine], he only has to come in
once a week for directly observed therapy [with rifapentine]," says Amina
Jindani of the St George's Medical School at the University of London, a
lead researcher in the study. "That's a huge advantage. It has enormous
potential."

Nathan Geffen of the Centre for Social Science Research at the University
of Cape Town applauds the study's findings but says Sanofi–Aventis, the
maker of the drug, is obliged to ensure that rifapentine is available in
the countries where the trials took place.

"In the Helsinki Declaration, which is suppose to guide the ethics of
clinical trials, it says that the intervention must be available in
the community in which it's tested once the trial's over," Geffen says.
"Here that's just not the case."

The US Food and Drug Administration (FDA) first registered rifa–pentine in
1998 after the drug was tested in South Africa.

"It's shameful that a significant amount of the research was conducted here
and it wasn't registered here," says Marcus Low of the Treatment Action
Campaign.

He also says the high price for the drug keeps it out of reach of the
majority of the world's patients. "At the current price there's
absolutely no prospect of the drug being used."

Low says that, although the rollout of rifapentine in South Africa is
probably far off for programmatic reasons, "if it was affordable,
there would be at least a discussion about whether we should change the
guidelines. But that's just not an option."

Plans to register the drug in SA

Sanofi–Aventis told the Mail & Guardian that it is planning to register the
drug in South Africa and hopes that it will come to market by 2015.

Prudence Mahapa, head of communications at Sanofi–Aventis South Africa,
says: "[The] Sanofi access to medicines policy is to have affordable
medicines for those who need it and rifapentine will follow this rule when
available in South Africa and in other countries."

Jindani says that, as the use of rifapentine rises, the price of the drug
is expected to fall.

Erica Lessem of the New York–based Treatment Action Group says that a
combination drug that includes both rifapentine and isoniazid – used for
preventing latent TB infection from turning into active disease – is likely
to be approved by the FDA in early 2014.

Mahapa says that Sanofi–Aventis is being unfairly targeted as it did not
conduct the study.

"Sanofi may not technically be the sponsor but donates the study drug and
has staff sitting on the protocol team," says Lessem. "It's hypocritical to
invest so much on the research side and then thwart access with drug
prices. Even in the US … rifapentine is too expensive to be routinely
accessible for programmes."

But Jindani warns that the world may not be ready for widespread
rifapentine use yet, noting that cost and registration are only part of
the problem. Rifapentine is better absorbed if it is taken with food and,
although meals were given during the clinical trial, this can't be assured
in the real world. Jindani also says that, because of its high price, it's
essential to see whether isoniazid can be used instead of moxifloxacin
during the first two months of treatment and achieve similar results.

A trial is currently being conducted to establish whether a TB drug regimen
containing moxifloxacin could reduce treatment from six months to four
months, significantly easing the burden on drug–sensitive TB patients.
There are 48 clinical trial sites currently testing the regimen, including
several in South Africa, and results are expected at the end of the year.
While Bayer has committed to reducing the price of moxifloxacin for TB use,
Jindani says that even if the price were halved, it could still be
prohibitively expensive. The TB Alliance, which is working with Bayer on
the so–called REMox trial, says it is committed to ensuring that all the
drugs it works on are affordable and accessible.

Some of Jindani's fellow researchers at St George's are hoping to test the
rifapentine regimen without these two factors but are awaiting funding.
Until that happens, Jindani says, "it's too early for general availability
for the drug".

Some TB drug prices are dropping. Last week, the Global Fund to Fight Aids,
TB and Malaria announced that it would begin buying a generic  of the
antibiotic linezolid, originally produced by the drug company Pfizer.

Although linezolid has been shown to be effective in treating
drug–resistant TB, the Pfizer product is expensive: in South Africa, it
costs R282 a pill in the public sector and R593 a pill in the private
sector. The Global Fund can now buy a version from the Indian
company Hetero for only R25 a tablet. It is hoped that a nod to the Hetero
product from the global fund may encourage other funding organisations and
national departments of health to begin buying the cheaper generic as well.



More information about the Ip-health mailing list